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Interleukin 2 exerts autocrine stimulation on murine
T-cell leukaemia growth
Cl Waidner, C Mongini, E Alvarez, M Sanchez Lockhart, MJ Gravisaco and SE Hajos
Cdtedra de Inmunologia, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, IDEHU: Instituto de Estudios de la Inmunidad Humoral, Argentina
Summary As it has been suggested that an autocrine mechanism may control tumour cell growth, in this work cells from a spontaneous
murine T lymphocyte leukaemia (LB) expressing the interleukin-2 receptor (IL-2R) (CD25) were evaluated in vitro for IL-2-mediated autocrine
growth. Cells grew readily in culture and proliferation was enhanced by the addition of recombinant IL-2 but inhibited by monoclonal
antibodies against either IL-2 or IL-2 receptor, in the absence of exogenous IL-2. Cyclosporin A also inhibited LB cell growth. However, when
exogenous IL-2 was added together with cyclosporin A, cell proliferation proved similar to controls. Using reverse transcription polymerase
chain reaction (PCR), mRNA for IL-2 was found to be present in tumour cells. Our findings support the hypothesis that LB tumour cell
proliferation is mediated by an autocrine pathway involving endogenous IL-2 generation, despite the fact that these cells are not dependent
on exogenous IL-2 to grow in culture.
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Autocrine generation of growth factors has been advanced as a
crucial component of tumorigenesis and autocrine secretion is
considered to play a majorrole in malignant transformation (Sporn
and Roberts, 1985; Goustin et al, 1986; Heldin and Westermark,
1989). A large number of studies have shown that growth factors
are capable of mediating both positive and negative proliferative
signals depending on the target cell (Waterfield, 1991). The release
ofimmunomodulatory factors by neoplasms seems quite common,
so that a variety of tumour-derived cytokines are liable to affect
the immune response by diverse pathways.
IL-2 itself is released by T lymphocytes following stimulation
by either antigen or mitogen and promotes long-term in vitro
growth ofnormal T cells through specific surface receptors, which
appear on activation (Robb et al, 1981; Minami et al, 1993) and are
transiently expressed (Smith, 1988). Although certain human T
cell leukaemia virus type I (HTLV-I) transformed cell lines estab-
lished in vitro in the presence ofIL-2 have become independent of
this cytokine, they still respond to and synthesize IL-2 (Arya et al,
1984). However, relatively few HTLV-I-transformed cell lines
behave likewise, suggesting that IL-2 may well stimulate their
growth by an autocrine pathway.
Previously, we have studied a spontaneous murine T cell
leukaemia, termed LB, which constitutively expresses the IL-2
receptor (CD25) (Lugasi et al, 1990), and we have also established
a cell line,LBC, derived from the LB tumour (Mongini et al, 1991,
1995), which so far has not been grown in the presence of IL-2,
and which bears IL-2 receptors on its cell surface similar to parent
cells. In addition, in previous work we have demonstrated that
LB cells release soluble IL-2R into the bloodstream and ascitic
fluid or into conditioned medium, thus inhibiting in vitro growth
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ofboth normal splenocytes and tumour cells themselves (Waldner
et al, 1994).
The present work was carried out to determine whether
autocrine stimulation by IL-2 was involved in LB cell growth. Our
results demonstrated that such growth was enhanced in response to
exogenous IL-2 but impaired in the presence ofeither anti-IL-2 or
anti-IL-2R monoclonal antibodies. In addition, mRNA for IL-2
was detected in LB cells. These results support the involvement of
autocrine IL-2 stimulation in the growth ofLB leukaemic cells.
MATERIALS AND METHODS
Mice
Normal BALB/c mice ofeither sex (2-4 months old), raised in the
animal colony at the Facultad de Farmacia y Bioquimica,
University of Buenos Aires, Argentina, and maintained on Cargill
pellets and water ad libitum, were used.
RPMI complete medium (RPMI-C)
RPMI-1640 (Gibco, Grand Island, NY, USA) was supplemented
with 10% fetal calfserum (FCS), 2 mM L-glutamine, 20 mm Hepes
buffer, 100 [tg ml-' penicillin, 150 ,tg ml-' streptomycin and 50 [tM
2-mercaptoethanol.
Tumours
LB lymphoid leukaemia arose spontaneously in a 6 month-old
BALB/c male mouse as a lymphocytic T-cell leukaemia (Ruggiero
et al, 1984), and this tumour was maintained by serial passing in
the peritoneal cavity ofsyngeneic hosts (Alvarez et al, 1989).
Drugs, cytokines and monoclonal antibodies
Recombinant murine IL-2 and monoclonal anti-IL-2 antibody
were purchased from Genzyme (USA); 7D4 monoclonal anti-IL-2
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monoclonal antibodies. Plates containing tumour cells were incu-
bated at37°C for24 h,then pulsedwith 1 RCi of[3H]thymidine (Du
Pont, NEN Products, Boston, MA, USA) for 24 h and harvested
with a semiautomatic Nunc cell harvester. Radioactivity incorpo-
rated into cells was measured by means ofa liquid scintillation beta
counter (Beckman, MD, USA). Results were expressed as mean
c.p.m. of incorporated [3H]thymidine in quadruplicate cultures.
Stimulation index (SI) foreach treatment was calculated as:
SI = [(c.p.m. exper. sample -c.p.m. control)/c.p.m. control)] x 100
Polymerase chain reaction for IL-2 mRNA
o+ ., - -
0,1 10
rlL-2 (IU ml[')
100
Figure 1 Effect of IL-2 on LB cell proliferation. Cells were cultured at 5 x 104
cells per well in RPMI-C (1% FCS or 2.5% FCS) in the presence or absence
of variable concentrations of murine recombinant IL-2. Results are expressed
as stimulation index (SI) calculated as described in Materials and methods.
Data represent means and s.d. of five experiments
receptor a chain antibody and control isotype monoclonal anti-
bodies from Pharmingen (USA); and cyclosporin A (CsA) from
Sandoz (Switzerland).
[3H]thymidine uptake by murine tumour cells
The assay was performed as already described (Waldner et al,
1994). Briefly, tumour cells were suspended in RPMI-C medium
and placed in round microtitre plates (2.5 x 105 cells per ml) (Nunc,
Denmark). Cell proliferation was determined in the presence or
absence of diverse concentrations of either CsA, cytokines or
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Total cellular RNA was isolated using TRIzol reagent (Gibco
BRL) according to the manufacturer's protocol. Briefly, 1 x 106
LB cells were collected and RNA was isolated using TRIzol
reagent, aguanidinium thiocyanate andphenol-containing reagent.
Total RNA was resuspended in DEPC-treated water and stored at
-70°C. cDNA was synthesized according to Current Protocols in
Immunology (Coligan et al, 1992), with slight modifications.
Briefly, 5 .tg oftotal RNA was mixed with DEPC-treated water to
make a total volume of 12.5 tl. The sample was incubated at 65°C
for 5 min. Subsequently, 50 U of RNAasin (Promega), 5 x RT
buffer, 1.5 [ig ofoligo (dT)15 (Promega), 3 Rg ofacetylated bovine
serum albuamin (BSA), 1 mm dNTP mix and 300 units of Mo-
MuLV reverse transcriptase (Gibco BRL) were added. The
mixture was incubated at 39°C for 1 h, followed by inactivation of
the enzyme at 95°C for 5 min.
PCR reaction was performed in 10 x PCR buffer, 80 FLM dNTP
mix, 50 pmol ofeach primer [5' primer site: AAC AGC GCA CCC
ACT TCA A and 3' primer site: TTG AGA TGA TGC TTT?GAC
A (Montgomery and Dallman, 1991)], 3 mm magnesium chloride,
1.25 units ofTaq polymerase (Gibco BRL) and cDNA. The cDNA
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Figure 2 Inhibition of LB cell proliferation by anti-IL-2 receptor antibody. Cells were cultured in RPMI (5% FCS) without addition of exogenous recombinant IL-2,
in the presence of purified 7D4 antibody or control isotype antibody at the indicated concentrations. Values represent the means of quadruplicate cultures s.d.
Data are representative of three experiments performed with similar results. The P-value for the maximum inhibition observed at 20 ,ug ml-' 7D4 monoclonal
antibody and the isotype control was < 0.0001
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Figure 3 Inhibition of LB cell proliferation by anti-IL-2 antibody. Cells were
cultured in RPMI-C (1% FCS) without addition of exogenous recombinant IL-
2, in the presence of purified anti-IL-2 antibody --*-- or control isotype
antibody - at the indicated concentrations. Values represent the means of
quadruplicate cultures ± s.d. Data are representative of three experiments
performed with similar results
was amplified in 30 cycles: denaturation for45 s at94°C,annealing
for 60 s at 600C and extension for 90 s at72°C, followed by a final
extension at 72°C for 10 min using a DNA Thermal Cycler Model
480 (Perkin Elmer Cetus Emeryville, CA, USA).
PCR products were analysed on a 2.5% agarose gel in 1 x TAE
containing 1 [ig ml-' ethidium bromide and visualized by UV tran-
sillumination.
Statistical analysis
Statistical analysis was performed by two-tailed Student's test for
independent samples, taking P < 0.05 as significant.
RESULTS
LB cells respond to exogenous IL-2
Under standard culture conditions, when LB cells were seeded at 1
x 106 cells per ml, growth required no addition ofexogenous IL-2
(Mongini et al, 1991). However, at lower concentrations, cells
grew poorly or not at all. The effect of IL-2 on cell growth was
measured by [3H]thymidine incorporation into cellular DNA. As
illustrated in Figure 1, cell proliferation was enhanced in a dose-
dependent fashion and a low concentration ofIL-2 (1 IU ml-' =2.2
x 10-2 nM) increased [3H]thymidine incorporation significantly (P
< 0.01). In all concentrations of IL-2 assayed, the maximum stim-
ulation index was observed using the lowest concentration ofFCS
(RPMI in 1% FCS). These results indicate that LB tumour cells
respond to IL-2 and that IL-2 receptors on LB cells are biologi-
cally functional.
Inhibition of LB cell proliferation by monoclonal
antibodies specific for IL-2R1a chain
As LB cells express functional IL-2 receptors on their surface, an
attempt was made to determine whether IL-2 receptors were essen-
tial for cell growth under standard culture conditions without addi-
tion of exogenous IL-2. Thus, the effect of anti-IL-2R antibodies
on LB proliferation was assessed by adding 7D4 monoclonal anti-
body to LB cultures. As shown in Figure 2, this antibody inhibited
-
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Figure 4 Effect of cyclosporin A (CsA) on LB proliferation in the presence or
absence of recombinant IL-2. Cells were cultured at 5 x 104 cells per well in
RPMI-C (2.5 x 105 cells per ml) in the presence or absence of CsA and/or 20
IU ml-' recombinant murine IL-2, then incubated for 2 days. [3H]Thymidine
was added to cultures during the last 24 h of incubation. Values represent
the means of quadruplicate cultures ± s.d. This assay is representative of
three experiments performed with similar results
LB cell proliferation, whereas the same subclass ofunrelated anti-
body (isotype control) at the same dilution failed to exert any
discernible effect.
On adding recombinant IL-2 in the presence of7D4 monoclonal
antibody, it was observed that this lymphokine counteracted the
effect caused by antibody binding to its receptor. As illustrated in
Figure 2, it was evident that inhibition owing to the interaction of
7D4 monoclonal antibody with the IL-2 receptor was dependent on
monoclonal antibody concentration and that addition ofexogenous
IL-2 at 50 IU ml' reversed such inhibition when 7D4 monoclonal
antibody was added to cultures within the 1-5 Vig ml-l range.
These results demonstrated that functional IL-2 receptors are
essential for LB cell growth.
Anti-IL-2 antibody inhibits LB cell growth
Anti-IL-2 antibody was added to LB cells in culture and
[3H]thymidine incorporation measured 2 days later. As shown in
Figure 3, cell proliferation was strongly inhibited by anti-IL-2
antibodies (roughly 90%) but not by unrelated antibody of the
same subclass (isotype control), demonstrating that in vitro LB
cell growth depends on autocrine IL-2 generation and that prolifer-
ation is mediated through the interaction of IL-2 receptors on the
cell surface with released IL-2.
Effect of CsA on LB cell growth
On the basis of the known effects of CsA on T cells, acting as an
immunosuppressive drug inhibiting the production of certain
lymphokines, evaluation was performed on LB cell proliferation.
CsA (0.01-0.5 [tg ml-) was added to LB cell cultures and
[3H]thymidine incorporation measured 2 days later. As shown in
Figure 4, CsA inhibited LB cell growth in a dose-dependent
fashion. Two days after addition of 0.5 [ig ml' CsA, LB cell
viability was determined by counting cells showing that cultures
contained mostly dead cells and debris.
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Figure 5 Analysis of products from PCR assay for IL-2 mRNA. The 453-bp
fragment is the IL-2-amplified product size. Lanes 2 and 5, Con A BALB/c
blasts (positive control); lanes 3 and 8, LB cells; lanes 4 and 7, 100-bp DNA
ladder, ranging in length from 100 to 1500 bp at 100-bp increments; lane 6,
reagent control
The effect of exogenous IL-2 addition was assayed on growth
inhibition induced by CsA, showing that LB cells cultured in the
presence of CsA plus recombinant IL-2 (20 IU ml-') grew much
like untreated control cells. However, in the absence of CsA, LB
tumour cells grew faster when recombinant IL-2 was added,
suggesting that the concentration of secreted IL-2 could act as a
limiting factor for LB cell growth (Figure 4).
RT-PCR for IL-2 transcripts in leukaemic cells
In order to confirm the endogenous production of IL-2, the pres-
ence of mRNA transcripts for IL-2 in LB cells was determined.
Total cellular RNA was isolated and was reverse transcribed to
cDNA and amplified by PCR. As shown in Figure 5, a 453-bp
fragment corresponds to the IL-2 amplified product size. IL-2
mRNA was detectable in LB cells as well as in normal blast cells
(positivecontrol). These results show that LB cells express mRNA
for IL-2, thus confirming that they produce IL-2 by themselves.
DISCUSSION
An autocrine pathway has been advanced to explain the control of
tumour cell growth,based on thefinding that tumourcells notonly
generate growth factors but are also responsive to such factors. In
this paper, we demonstrated that an autocrine mechanism is
responsible for the regulation of LB tumour cell proliferation
through the IL-2 cytokine.
LB is a T cell leukaemia constitutively expressing IL-2 recep-
tors on its surface (Lugasi et al, 1990). As already stated, both the
LB ascitic tumour and the LBC cell line are capable ofgrowing in
vitro without the addition ofexogenous IL-2 (Mongini et al, 1991,
1996). In this paper, we demonstrate the mitogenic effect of IL-2
on LB cells, particularly at low fetal calf serum concentrations,
suggesting that IL-2 receptors expressed on LB cells are able to
generate signals leading to cell proliferation. Duprez et al (1985)
have described a human T cell line (IARC 301) initially estab-
lished in vitro in the absence of exogenous IL-2 and expressing
functional IL-2 receptors similar to those on LB cells, which may
proliferate by self-stimulation with IL-2 secreted by the cell itself.
In contrast, most adult T leukaemia (ATL) and derived cell lines
fail to do so in response to IL-2 (Yodoi et al, 1992).
We have demonstrated that IL-2 stimulates the growth of LB
cells in autocrine fashion, as antibodies specific for IL-2 as well as
IL-2Ra chain are capable ofinhibiting their in vitro growth, in the
absence ofexogenous IL-2. Furthermore, on studying the effect of
7D4 monoclonal antibody specific for IL-2Ra chain on LB, cell
proliferation proved to be dependent on the monoclonal antibody,
and the effect was reversed by IL-2 in a dose-dependent manner.
Such behaviour agrees with findings described by others who
showed that 7D4 antibody lowers IL-2 proliferation but fails to
inhibit IL-2 binding to its receptor (Malek et al, 1984).
At variance with the effect ofIL-2R on normal activated Tcells,
receptors on ATL cells and on derived cell lines could not be
down-regulated (Tsudo et al, 1983) or modulated by anti-IL-2R
monoclonal antibodies (Uchiyama et al, 1981). Indeed, a chain
overexpression is closely associated with T cell immortalization
(Farcet et al, 1991). LB cells not only express IL-2 receptors,
but their growth is also inhibited by monoclonal antibodies
directed against IL-2 receptors. The capability of both anti-
IL-2 and anti-IL-2 receptor antibodies to inhibit in vitro cell
growth demonstratedthe autocrine effect ofIL-2 on LB cells,most
likely because tumour cells depend on their endogenous IL-2
production. Thus, proliferation is probably mediated through
binding ofIL-2 receptors on the cell surface with IL-2 released by
the cells themselves.
RT-PCR assay demonstrated that LB cells constitutively tran-
scribe the IL-2 gene. This result agrees with findings from other
authors that described the presence ofa low level ofmRNA forIL-
2 in human leukaemic cells (Farcet et al, 1991) and in otherhuman
carcinomas (Yasamura et al, 1994; Lin etal, 1995). While LB cells
may secrete the IL-2 required for their own growth, its concentra-
tion in the culture medium may remain low, as it is constantly
internalized into cells and degraded after binding to high-affinity
surface receptors, which seems to explain why IL-2 could not be
detected in conditioned medium ofLB cells (data not shown).
It has been shown that IL-15 shares many biological properties
of IL-2, binds to IL-2RP and IL-2Ry and competes with IL-2 for
binding to the IL-2R (Grabstein et al, 1994). Based on these
previous findings, we have examined the IL-15 capacity of stimu-
lating LB cell proliferation. Our preliminary results have shown
that the human recombinant IL-15 concentration necessary to
stimulate LB cell proliferation (data not shown) was similar to that
needed to stimulate human NK cells expressing high-affinity IL-
2R (Carson et al, 1994). These results, in addition to the concen-
trations of IL-2 required for in vitro LB cell growth stimulation,
suggest that LB cells could express the high-affinity IL-2R.
As a potent immunosuppressive agent, CsA inhibits the prolif-
eration of helper and cytotoxic T cells by inhibiting lymphokine
production (Hess, 1993). Our results indicate that, while CsA
inhibits IL-2-dependent LB cell growth, it has been proved not to
affect proliferation of JURKAT leukaemic T cells, whose growth
is IL-2 independent (Dautry-Varsat et al, 1988). The results ofcell
viability could suggest that CsA exerted a cytotoxic effect on LB
cells.However, ourfindings showedthat CsA inhibition ofLB cell
growth was reversed by simultaneous addition ofexogenous IL-2,
indicating that CsA could hardly be cytotoxic for LB cells, since it
only inhibited endogenous IL-2 production. Growth inhibition by
CsA and its reversal by IL-2 may provide a useful tool to deter-
mine whether cell line or tumour cell growth is controlled by an
autocrine mechanism involving IL-2.
Taking all available data into consideration, it may thus be
concluded that IL-2 is an essential requirement for LB tumour
growth and that LB leukaemia represents a valid experimental
model for studying intracellular events arising from autocrine
growth stimulation mediated by IL-2.
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